Tag: Viral Genetics and Evolution

1460 PP2Ac deficiency enhances tumor immunogenicity by activating STING-Type I interferon signaling in glioblastoma

Background Glioblastoma (GBM) is an immunologically ‘cold’ tumor that does not respond to current immunotherapy. Low immunogenicity of GBM with minimal MHC-I expression and paucity of T cells infiltration are major barriers for effective immune checkpoint blockade (ICB).1–4 PP2A is a major protein phosphatase that account for 50% to 70% of the total serine/threonine phosphatase… Continue reading 1460 PP2Ac deficiency enhances tumor immunogenicity by activating STING-Type I interferon signaling in glioblastoma

1405 Comparative analysis of complete blood count, serum chemistry and immune phenotype between SRG and CD rats

AI SummaryThe study compares the immune characteristics of immunodeficient SRG rats with control CD rats. It found that SRG rats have reduced levels of T, B, and NK cells, but similar levels of monocytes. SRG rats also have increased complement activity compared to CD rats. The study concludes that these findings enhance our understanding of… Continue reading 1405 Comparative analysis of complete blood count, serum chemistry and immune phenotype between SRG and CD rats

1101 Activation of myeloid cells suppresses metastatic ovarian cancer via tumoricidal neutrophils and IL-27-secreting macrophages

AI SummaryResearchers have developed a novel immunotherapy that activates myeloid cells to eradicate metastatic ovarian cancer (OC). Using β-glucan and interferon (IFN), the study found that combining these treatments cleared ascites and reduced total metastases in mice. This therapy required T cells and non-tumor IFN signaling in the host. The activation of myeloid cells led… Continue reading 1101 Activation of myeloid cells suppresses metastatic ovarian cancer via tumoricidal neutrophils and IL-27-secreting macrophages

797 Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer

Background Combination of eribulin and immune checkpoint inhibitor (ICI) showed durable response for HER-2 negative metastatic breast cancer (MBC) patients, but PD-L1 expression was not associated with efficacy. Here, we report the whole exome sequencing (WES) and whole transcriptome sequencing (WTS) analysis of pretreatment tumor tissues from the phase II clinical trial of the eribulin… Continue reading 797 Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2 negative metastatic breast cancer

557 Chronicity of exposure and ensuing resistance to platinum chemotherapy sensitizes homologous recombination-deficient pancreatic ductal adenocarcinoma to immune checkpoint blockade

AI SummaryPancreatic cancer patients with deficiencies in homologous recombination are initially treated with platinum-based chemotherapy but can become resistant. Researchers found that patients who developed resistance to platinum chemotherapy responded well to immune checkpoint blockade (ICB) treatment. In a preclinical study, mice with platinum-resistant pancreatic cancer cells also showed reduced tumor growth when treated with… Continue reading 557 Chronicity of exposure and ensuing resistance to platinum chemotherapy sensitizes homologous recombination-deficient pancreatic ductal adenocarcinoma to immune checkpoint blockade

418 The development of ‘off-the-shelf manufacturing strategies of iPSC-based gamma-delta T cells

Background Gamma-delta () T cells are depleted during cancer progression resulting in the progressive loss of anti-cancer activity. Elevated numbers of T cells are associated with greater survival outcomes in both hematopoietic and solid malignancies. Induced pluripotent stem cell (iPSC) derived T cells could address the therapeutic challenges of multiple allogeneic T cell infusions as… Continue reading 418 The development of ‘off-the-shelf manufacturing strategies of iPSC-based gamma-delta T cells

185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

AI SummaryCopy number aberrations (CNAs) can be used as an alternative approach to predict responses to immune checkpoint inhibitors in lung cancer patients. The study found that a higher total copy number burden (TCB) was associated with poorer overall survival in lung cancer patients. Homologous recombination deficiency (HRD) score was significantly associated with unfavorable survival… Continue reading 185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

75 The mutational landscape defines the proteome and spatial organization of tumor, stroma, and immune cells in ovarian cancer

Background High-grade serous ovarian cancer (HGSOC) is highly aggressive and lethal, with clinical challenges to both diagnosis and treatment. The genomic instability of HGSOC, further complicated by homologous recombination deficiency (HRD), leads to heterogeneity in the HGSOC tumors and patient response to treatment. We have previously profiled the complete proteome of tumors from 32 HGSOC… Continue reading 75 The mutational landscape defines the proteome and spatial organization of tumor, stroma, and immune cells in ovarian cancer